By Ted Bosworth
Updated guidelines from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) for the treatment of hepatitis C have identified preferred regimens for patients with decompensated cirrhosis and for other unique populations, such as those with renal impairment.
The recommendations have been divided into a list of variables, including genotype, status of liver function, prior treatment and eligibility for ribavirin